Matching articles for "Lynparza"
In Brief: A New Prostate Cancer Indication for Olaparib (Lynparza) (online only)
The Medical Letter on Drugs and Therapeutics • June 26, 2023; (Issue 1679)
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor olaparib (Lynparza – AstraZeneca) has now
been approved by the FDA for use in combination
with abiraterone (Zytiga, and others) and either
prednisone...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor olaparib (Lynparza – AstraZeneca) has now
been approved by the FDA for use in combination
with abiraterone (Zytiga, and others) and either
prednisone or prednisolone for treatment of adults
with deleterious or suspected deleterious BRCA-mutated
(BRCAm) metastatic castration-resistant
prostate cancer (mCRPC). Olaparib was previously
approved by the FDA for treatment of adults with
deleterious or suspected deleterious germline or
somatic homologous recombinant repair (HRR) genemutated
mCRPC who progressed on prior treatment
with enzalutamide (Xtandi) or abiraterone.
In Brief: Olaparib (Lynparza) for High-Risk Early Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • April 17, 2023; (Issue 1674)
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor olaparib (Lynparza – AstraZeneca) has been
approved by the FDA for adjuvant treatment of adults
with deleterious or suspected deleterious...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor olaparib (Lynparza – AstraZeneca) has been
approved by the FDA for adjuvant treatment of adults
with deleterious or suspected deleterious germline
BRCA-mutated (gBRCAm), human epidermal growth
factor receptor 2 (HER2)-negative, high-risk early
breast cancer who received prior neoadjuvant or
adjuvant chemotherapy. The drug was previously
approved for treatment of adults with deleterious
or suspected deleterious gBRCAm, HER2-negative
metastatic breast cancer who received chemotherapy
in the neoadjuvant, adjuvant, or metastatic setting.
Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • February 8, 2021; (Issue 1617)
The FDA has approved sacituzumab govitecan-hziy
(Trodelvy – Immunomedics), a trophoblast cell-surface
antigen-2 (Trop-2)-directed antibody and topoisomerase
inhibitor conjugate, for treatment of adults...
The FDA has approved sacituzumab govitecan-hziy
(Trodelvy – Immunomedics), a trophoblast cell-surface
antigen-2 (Trop-2)-directed antibody and topoisomerase
inhibitor conjugate, for treatment of adults with metastatic
triple-negative breast cancer who have received ≥2 prior
therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.
PARP Inhibitors for Ovarian Cancer
The Medical Letter on Drugs and Therapeutics • December 4, 2017; (Issue 1535)
Three oral poly(ADP-ribose) polymerase (PARP)
inhibitors have been approved by the FDA for treatment
of advanced, recurrent ovarian cancer. Olaparib
(Lynparza – AstraZeneca), niraparib (Zejula –...
Three oral poly(ADP-ribose) polymerase (PARP)
inhibitors have been approved by the FDA for treatment
of advanced, recurrent ovarian cancer. Olaparib
(Lynparza – AstraZeneca), niraparib (Zejula – Tesaro),
and rucaparib (Rubraca – Clovis) are each approved
for somewhat different indications and for patients
with different biomarkers (see Table 2).
Olaparib (Lynparza) for Advanced Ovarian Cancer (online only)
The Medical Letter on Drugs and Therapeutics • February 29, 2016; (Issue 1489)
The FDA has approved the oral poly (ADP-ribose) polymerase
(PARP) inhibitor olaparib (Lynparza – Astra-Zeneca) as monotherapy for treatment of women with
advanced ovarian cancer who have BRCA1/2...
The FDA has approved the oral poly (ADP-ribose) polymerase
(PARP) inhibitor olaparib (Lynparza – Astra-Zeneca) as monotherapy for treatment of women with
advanced ovarian cancer who have BRCA1/2 germline
mutations and have received at least 3 prior lines of
chemotherapy. Olaparib is the first PARP inhibitor to
be approved in the US. It is approved outside the US
for maintenance treatment of relapsed BRCA-mutated
ovarian cancer.